市場調查報告書
商品編碼
1468636
2024-2032 年胰臟癌治療和診斷市場報告(按類型(診斷、治療)、應用(醫院、診所等)和地區)Pancreatic Cancer Therapeutics and Diagnostics Market Report by Type (Diagnostics, Treatment), Application (Hospitals, Clinics, and Others), and Region 2024-2032 |
IMARC Group年,全球胰臟癌治療及診斷市場規模達43億美元。蓬勃發展的醫療保健行業、胰腺癌患病率的上升以及對殺死胰腺癌細胞的化療的需求不斷增加是推動市場發展的一些關鍵因素。
胰臟癌治療和診斷是用於診斷胰臟癌並提供治療的醫療程序。這些治療和診斷包括超音波、電腦斷層掃描 (CT) 掃描、磁振造影 (MRI) 和正子斷層掃描 (PET) 掃描。他們依靠超音波內視鏡 (EUS),使用超音波設備從腹部內部生成胰臟影像。由於胰臟細胞生長失控,它們有助於監測腫瘤的位置。他們協助進行活組織檢查,取出一小部分組織樣本,以便在顯微鏡下檢查。它們還有助於實驗室檢查,例如全血細胞計數 (CBC)、膽道阻塞的肝臟酵素測試以及空腹血糖和糖化血紅蛋白 (HbA1C) 測試。因此,胰臟癌的治療和診斷在全球的醫院和專科中心得到了應用。
目前,由於老年人口增加和群眾過度吸菸習慣導致胰臟癌盛行率上升,是支撐市場成長的關鍵因素之一。除此之外,世界範圍內分子生物學、藥物和診斷技術的發展也在不斷發展。這與蓬勃發展的醫療保健產業目前正在推動市場的成長。此外,透過阻止胰臟癌細胞生長和分裂來殺死胰臟癌細胞的化療需求不斷增加,對市場產生了積極影響。此外,多個國家的管理機構正在大力投資胰臟癌臨床試驗和脫氧核糖核酸(DNA)修復抑制劑合併化療。他們也致力於透過批准臨床階段的藥物來促進胰腺癌治療和診斷的發展。除此之外,該行業的主要參與者正在推出一種人源化單株抗體,該抗體可促進抗腫瘤免疫反應,以治療食道癌和胃食道交界處以及胰腺癌。他們也正在開發和推出基於試劑盒的測試,透過確定 BRCA1 和 BRCA2 變異並評估基因組不穩定性來檢測胰臟癌,預計這將有助於未來幾年市場的成長。
The global pancreatic cancer therapeutics and diagnostics market size reached US$ 4.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.51% during 2024-2032. The burgeoning healthcare industry, rising prevalence of pancreatic cancer, and the escalating demand for chemotherapy to kill pancreatic cancer cells represent some of the key factors driving the market.
Pancreatic cancer therapeutics and diagnostics are medical procedures used to diagnose pancreatic cancer and provide treatment. These therapeutics and diagnostics comprise ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. They rely on an endoscopic ultrasound (EUS) that uses an ultrasound device to produce images of the pancreas from inside the abdomen. They help in monitoring the location of the tumor due to an uncontrollable growth of cells in the pancreas. They assist in performing a biopsy to remove a small sample of tissue for examination under a microscope. They also aid in laboratory investigations, such as a complete blood count (CBC), liver enzyme tests for biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. As a result, pancreatic cancer therapeutics and diagnostics find applications in hospitals and specialty centers across the globe.
At present, the rising prevalence of pancreatic cancer due to the increasing geriatric population and excessive smoking habits among the masses represents one of the key factors supporting the growth of the market. Besides this, there is an increase in the development of molecular biology, drugs, and diagnostic technology around the world. This, along with the thriving healthcare industry, is currently propelling the growth of the market. In addition, the escalating demand for chemotherapy to kill pancreatic cancer cells by preventing them from growing and dividing is positively influencing the market. Moreover, governing agencies of several countries are extensively investing in pancreatic cancer clinical trial testing and deoxyribonucleic acid (DNA) repair inhibitors combined with chemotherapy. They are also focusing on enhancing the growth of pancreatic cancer therapeutics and diagnostics by approving drugs in the clinical phase. Apart from this, key players operating in the industry are introducing a humanized monoclonal antibody that promotes the anti-tumor immune response for treating esophageal and gastroesophageal junction and pancreatic cancer. They are also developing and introducing kit-based testing to detect pancreatic cancer by determining BRCA1 and BRCA2 variants and assessing genomic instability, which is projected to contribute to the growth of the market in the coming years.
IMARC Group provides an analysis of the key trends in each segment of the global pancreatic cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type and application.
Diagnostics
Imaging
Biopsy
Endoscopic Ultrasound
Others
Treatment
Targeted Therapies
Chemotherapy
Surgery
Others
The report has provided a detailed breakup and analysis of the pancreatic cancer therapeutics and diagnostics market based on the type. This includes diagnostics (imaging, biopsy, endoscopic ultrasound, and others) and treatment (targeted therapies, chemotherapy, surgery, and others). According to the report, treatment accounted for the largest market share.
Hospitals
Clinics
Others
A detailed breakup and analysis of the pancreatic cancer therapeutics and diagnostics market based on application has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals represented the leading segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for pancreatic cancer therapeutics and diagnostics. Some of the factors driving the North America pancreatic cancer therapeutics and diagnostics market included advancements in diagnostic technologies, emerging therapies and treatment options, increasing healthcare expenditure, and government initiatives and funding.
The report has also provided a comprehensive analysis of the competitive landscape in the global pancreatic cancer therapeutics and diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies include AstraZeneca plc, F. Hoffmann-La Roche Ltd., Immunovia AB, Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.